MRNS - Marinus Pharmaceuticals, Inc.
| Previous Close | 1.1100 |
| Open | 1.1300 |
| Bid | 1.0700 x 27000 |
| Ask | 1.1800 x 1300 |
| Day's Range | 1.0700 - 1.1600 |
| 52 Week Range | 0.7700 - 10.5400 |
| Volume | 689,471 |
| Avg. Volume | 909,237 |
| Market Cap | 56.785M |
| Beta (3Y Monthly) | 3.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9820 |
| Earnings Date | Aug 2, 2018 - Aug 3, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.14 |
- GlobeNewswire
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 68,000 shares of its common stock to new employees, with a grant date of August 21, 2019. The options will vest and become exercisable as to 25 percent of the shares on the one-year anniversary of the recipient's start date, and will vest and become exercisable as to the remaining 75 percent of the shares in 36 equal monthly installments at the end of each month following the anniversary, subject to the employee's continued employment with Marinus on such vesting dates. The stock options were granted as inducements material to the new employees entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant.
- Zacks
Are Options Traders Betting on a Big Move in Marinus (MRNS) Stock?
Investors need to pay close attention to Marinus (MRNS) stock based on the movements in the options market lately.
- American City Business Journals
Main Line pharmaceutical firm finds new CEO in-house
Marinus Pharmaceuticals Inc. has appointed Dr. Scott Braunstein as CEO. For the past six months Braunstein served as executive chairman of the Radnor pharmaceutical company. Marinus is focused on developing its lead drug candidate ganaxolone as a treatment for epilepsy, depression and otherneuropsychiatric disorders.
- GlobeNewswire
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter Financial Results
Marinus Pharmaceuticals, Inc. (MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the second quarter ended June 30, 2019. “I am proud to announce that after an extensive interview process with several qualified candidates, the Board has appointed me as Chief Executive Officer of Marinus,” commented Dr. Scott Braunstein, formerly Executive Chairman of Marinus. “As Executive Chairman, the past six months have been both invigorating and challenging as I worked with the Marinus team to continue to unlock the value potential of ganaxolone.
- Motley Fool
Here's Why Marinus Pharmaceuticals Stock Is Collapsing Today
Wall Street is not sold on the latest clinical results.
- Benzinga
Marinus Sinks To 2-Year Low As Postpartum Depression Drug Found Ineffective At 28 Days
Marinus — a pharma company that focuses on developing therapies for epilepsy, depression and other neuropsychiatric disorders — announced results from the second part of a Phase 2 Magnolia clinical trial that evaluated intravenous ganaxolone in women with postpartum depression, or PPD. The results showed that the Hamilton Rating Scale for Depression, or HAM-D17, scores at 28 days of treatment were the same as a placebo.
- GlobeNewswire
Marinus Pharmaceuticals Announces Data from Magnolia and Amaryllis Phase 2 Studies in Women with Postpartum Depression
Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders, today announced intravenous (IV) ganaxolone results from Part 2 of its Phase 2 Magnolia clinical trial, evaluating IV ganaxolone followed by daily oral ganaxolone in women with postpartum depression (PPD). The results showed that, in the study, ganaxolone administered as a six-hour infusion followed by oral administration was generally safe, well-tolerated and provided clinically meaningful reductions in Hamilton Rating Scale for Depression (HAM-D17) scores at early time points of 6 hours and 24 hours after start of treatment.
- Insider Monkey
Is Marinus Pharmaceuticals Inc (MRNS) A Good Stock To Buy?
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
- MarketWatch
5 stocks trading at under $10 worth discovering
This seems weird, because stock price alone tells you nothing about the merits of an investment. If you turn to the stock market for thrills, you should put all your money in CDs. As market expert Martin Pring once pointed out, the stock market is designed to exploit your character flaws to take your money.
- Simply Wall St.
Announcing: Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Increased An Energizing 187% In The Last Three Years
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
- GlobeNewswire
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 105,000 shares of its common stock to five new employees, with a grant date of January 24, 2019. The options will vest and become exercisable as to 25 percent of the shares on the one-year anniversary of the recipient's start date, and will vest and become exercisable as to the remaining 75 percent of the shares in 36 equal monthly installments at the end of each month following the anniversary, subject to the employee's continued employment with Marinus on such vesting dates. The stock options were granted as inducements material to the new employees entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant.
- GlobeNewswire
Marinus Pharmaceuticals to Participate at Upcoming Investor Conferences
Marinus Pharmaceuticals, Inc. (MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Dr. Scott Braunstein, executive chairman of Marinus, will be presenting at the Jefferies 2019 Healthcare Conference on Friday June 7, 2019 at 9:30 a.m. ET. The conference will take place in New York City. In addition, Dr. Braunstein will be participating on a panel discussion entitled, “Orphan Developmental Disorders” at the JMP Securities Life Science Conference on June 19, 2019 at 10:00 a.m. ET.
- Zacks
Pfizer's (PFE) Epilepsy Drug Lyrica Fails in Phase III Study
Pfizer (PFE) announces failure of a phase III study evaluating Lyrica in patients with primary generalized tonic-clonic seizures, a form of epilepsy.
- Associated Press
Marinus Pharmaceuticals: 1Q Earnings Snapshot
On a per-share basis, the Radnor, Pennsylvania-based company said it had a loss of 24 cents. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
- GlobeNewswire
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2019 Financial Results
Marinus Pharmaceuticals, Inc. (MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the first quarter ended March 31, 2019. “In 2019, Marinus continues to advance its ganaxolone clinical programs for PPD, orphan pediatric genetic epilepsies and refractory status epilepticus,” said Dr. Scott Braunstein, executive chairman of Marinus. “We have seen strong enrollment trends across our Phase 2 programs and have decided to take advantage of this interest and increase the size of all three of these studies with minimal impact to timelines. Both PPD studies are fully enrolled and we will be expanding our RSE cohorts to include up to 20 patients. As a result, we expect data from the PPD studies in the first half of the third quarter and data from the RSE study by the end of the third quarter.
- Simply Wall St.
How Much Of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Do Institutions Own?
Every investor in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller...
- Zacks
Implied Volatility Surging for Marinus Pharmaceuticals (MRNS) Stock Options
Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.
- Zacks
Factors Setting the Tone for Oracle's (ORCL) Q3 Earnings
Oracle (ORCL) is benefiting from increasing adoption of its product portfolio and synergies from strategic buyouts.
- Zacks
Broadcom (AVGO) to Report Q1 Earnings: What's in the Offing?
Broadcom (AVGO) extensive product portfolio is likely to positively impact the to-be-reported quarter's results.
- GlobeNewswire
Marinus Pharmaceuticals Provides Business Update and 2018 Financial Results
Marinus Pharmaceuticals, Inc. (MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a business update on its clinical development activities and reported its financial results for the year ended December 31, 2018. “2018 was a pivotal year for Marinus, kicking off the first-ever single pivotal Phase 3 study in children with CDKL5 deficiency disorder, and reporting positive results from Part 1 of our Magnolia Study with IV ganaxolone in women with postpartum depression,” said Christopher M. Cashman, CEO of Marinus. Dr. Scott Braunstein, Executive Chairman of Marinus commented, “Through the multiple clinical studies conducted to date, we have shown that ganaxolone is safe, well-tolerated and effective in reducing seizures, anxiety and depression.
- GlobeNewswire
Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related Epilepsy
Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that it is initiating a single global pivotal Phase 3 clinical study (Violet Study) evaluating oral ganaxolone in children with PCDH19-related epilepsy (PCDH19-RE), a rare genetic epilepsy. If successful, the Violet Study is intended to support the regulatory filings for approval of ganaxolone in this underserved and refractory patient population. The Violet Study is a global, double-blind, randomized, placebo-controlled pivotal Phase 3 clinical study evaluating ganaxolone in children with PCDH19-RE.
- Benzinga
Jefferies Sees Opportunity In Marinus Pharmaceuticals: 4 Reasons Why
Shares of Marinus Pharmaceuticals Inc (NASDAQ: MRNS ), a micro-cap biotech focused on therapies for neuropsychiatric disorders, are likely to see upside amid some key near-term events, according to Jefferies. ...
- GlobeNewswire
Marinus Pharmaceuticals to Present at the Cowen Healthcare Conference
Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Edward Smith, Chief Financial Officer, will present a company overview at the 39th Annual Cowen and Company Healthcare Conference on Monday, March 11, 2019 at 4:10 p.m. ET. Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders.
- American City Business Journals
Main Line biopharm CEO stepping down
A Main Line biopharmaceutical company is searching for a new chief executive officer. Marinus Pharmaceuticals of Radnor said Tuesday its CEO, Christopher Cashman, is leaving the company effective March 18 to pursue other opportunities. In an interview with the Philadelphia Business Journal, Cashman said he would classify his departure as a "mutual" decision.
- GlobeNewswire
Marinus Announces Leadership Transition
Marinus Pharmaceuticals, Inc. (MRNS) (“Marinus” or the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that chief executive officer, Christopher M. Cashman, will leave the Company to pursue other opportunities in the life science industry effective March 18, 2019. Scott Braunstein, M.D., currently a director on the Company’s Board, has been appointed executive chairman. Marinus has retained an executive search firm to identify Mr. Cashman’s successor as CEO.
